ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 18c
Tweet
Share
E-mailGet Alerts ATRA Hot Sheet
Join SI Premium – FREE
ATARA Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of ($0.62), $0.18 worse than the analyst estimate of ($0.44).
For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Upgrades Casey's General Stores (CASY) to Outperform, 'Opportunity Knocks'
- UBS Upgrades Cytokinetics (CYTK) to Buy
- TD Cowen Upgrades PBF Energy (PBF) to Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
